SLC5A2 and diabetes mellitus: Similarly, sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed for diabetes management, have shown remarkable cardiovascular benefits in heart failure patients but have had the same hemodynamic consequences (Rong et al, 2020).